Earlier we reported publication of the first results of the Diagnode-1 and Diagnode-2 studies, testing Diamyd Medical's diabetes vaccine GAD-alum (Diamyd®) in people with recently diagnosed type 1 diabetes. Diamyd Medical is now recruiting people for the Diagnode 3 study.

The Diagnode-1 and Diagnode-2 studies showed that intralymphatic injection of diabetes vaccine GAD-alum (Diamyd®) combined with vitamin supplementation is a safe treatment, resulting in a slower decrease in C-peptide (i.e. insulin) production, mainly for recently diagnosed people with type 1 diabetes carrying the HLA DR3-DQ2 haplotype. 

 

Diamyd Medical is now recruiting people with recently diagnosed type 1 diabetes (< 6 months) and with the HLA DR3-DQ2 haplotype for the Diagnode 3 study.  As for the Diagnode 1 and 2 studies, Diabeter is also participating center in de Diagnode 3 study and eligible people can contact us at research@diabeter.nl for more information.